Piper Sandler Raises Masimo (NASDAQ:MASI) Price Target to $215.00

Masimo (NASDAQ:MASI) had its price objective lifted by Piper Sandler from $210.00 to $215.00 in a research note published on Wednesday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the medical equipment provider’s stock.

Several other research firms also recently commented on MASI. Wells Fargo & Company boosted their target price on Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a report on Wednesday. Raymond James upped their price target on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, December 27th. Stifel Nicolaus restated a “buy” rating and set a $190.00 price objective (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Wednesday. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $194.80.

Masimo Stock Up 1.4 %

NASDAQ:MASI opened at $188.77 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The firm’s 50-day moving average price is $173.28 and its 200-day moving average price is $153.33. The company has a market capitalization of $10.11 billion, a PE ratio of 130.19 and a beta of 1.02. Masimo has a 1-year low of $101.61 and a 1-year high of $192.62.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $600.70 million for the quarter, compared to analysts’ expectations of $593.35 million. On average, equities analysts predict that Masimo will post 4.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Masimo

Several hedge funds and other institutional investors have recently bought and sold shares of MASI. FMR LLC lifted its position in Masimo by 41.2% during the third quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock valued at $900,860,000 after purchasing an additional 1,970,883 shares during the period. Capital Research Global Investors lifted its holdings in shares of Masimo by 80.5% during the 4th quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider’s stock valued at $405,807,000 after buying an additional 1,094,647 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in shares of Masimo by 119.0% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider’s stock worth $286,823,000 after buying an additional 943,001 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of Masimo by 1,276.9% in the fourth quarter. Alliancebernstein L.P. now owns 947,391 shares of the medical equipment provider’s stock worth $156,604,000 after acquiring an additional 878,587 shares during the period. Finally, Corient Private Wealth LLC increased its position in Masimo by 8,847.1% during the fourth quarter. Corient Private Wealth LLC now owns 347,683 shares of the medical equipment provider’s stock valued at $57,472,000 after acquiring an additional 343,797 shares during the last quarter. Institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.